1. Does the Dose of Standard Adjuvant Chemotherapy Affect the Triple-negative Breast Cancer Benefit from Extended Capecitabine Metronomic Therapy? An Exploratory Analysis of the SYSUCC-001 Trial
- Author
-
Chen,Ying, Li,Wen-Xia, Wu,Jia-Hua, Chen,Geng-Hang, Yang,Chun-Min, Lu,Hai, Wang,Xi, Wang,Shu-Sen, Huang,Heng, Cai,Li, Zhao,Li, Peng,Rou-Jun, Lin,Ying, Tang,Jun, Zeng,Jian, Zhang,Le-Hong, Ke,Yong-Li, Wang,Xian-Ming, Liu,Xin-Mei, Zhang,An-Qin, Xu,Fei, Bi,Xi-Wen, Huang,Jia-Jia, Li,Ji-Bin, Pang,Dan-Mei, Xue,Cong, Shi,Yan-Xia, He,Zhen-Yu, Lin,Huan-Xin, An,Xin, Xia,Wen, Cao,Ye, Guo,Ying, Hong,Ruo-Xi, Jiang,Kui-Kui, Zhong,Yong-Yi, Zhang,Ge, Tienchaiananda,Piyawan, Oikawa,Masahiro, Yuan,Zhong-Yu, Chen,Qian-Jun, Chen,Ying, Li,Wen-Xia, Wu,Jia-Hua, Chen,Geng-Hang, Yang,Chun-Min, Lu,Hai, Wang,Xi, Wang,Shu-Sen, Huang,Heng, Cai,Li, Zhao,Li, Peng,Rou-Jun, Lin,Ying, Tang,Jun, Zeng,Jian, Zhang,Le-Hong, Ke,Yong-Li, Wang,Xian-Ming, Liu,Xin-Mei, Zhang,An-Qin, Xu,Fei, Bi,Xi-Wen, Huang,Jia-Jia, Li,Ji-Bin, Pang,Dan-Mei, Xue,Cong, Shi,Yan-Xia, He,Zhen-Yu, Lin,Huan-Xin, An,Xin, Xia,Wen, Cao,Ye, Guo,Ying, Hong,Ruo-Xi, Jiang,Kui-Kui, Zhong,Yong-Yi, Zhang,Ge, Tienchaiananda,Piyawan, Oikawa,Masahiro, Yuan,Zhong-Yu, and Chen,Qian-Jun
- Abstract
Ying Chen,1,2,* Wen-Xia Li,1,2,* Jia-Hua Wu,1,2 Geng-Hang Chen,2 Chun-Min Yang,1,2 Hai Lu,1,2 Xi Wang,3 Shu-Sen Wang,4 Heng Huang,5 Li Cai,6 Li Zhao,7 Rou-Jun Peng,8 Ying Lin,9 Jun Tang,3 Jian Zeng,10 Le-Hong Zhang,11 Yong-Li Ke,12 Xian-Ming Wang,13 Xin-Mei Liu,14 An-Qin Zhang,15 Fei Xu,4 Xi-Wen Bi,4 Jia-Jia Huang,4 Ji-Bin Li,16 Dan-Mei Pang,17 Cong Xue,4 Yan-Xia Shi,4 Zhen-Yu He,18 Huan-Xin Lin,18 Xin An,4 Wen Xia,4 Ye Cao,16 Ying Guo,16 Ruo-Xi Hong,4 Kui-Kui Jiang,4 Yong-Yi Zhong,4 Ge Zhang,19 Piyawan Tienchaiananda,20 Masahiro Oikawa,21 Zhong-Yu Yuan,4 Qian-Jun Chen22,23 1Department of Breast Surgery, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Peopleâs Republic of China; 2Department of Breast Surgery, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Peopleâs Republic of China; 3Department of Breast Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Peopleâs Republic of China; 4Department of Medical Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Peopleâs Republic of China; 5Department of Breast Oncology, Lianjiang Peopleâs Hospital, Lianjiang, Peopleâs Republic of China; 6Department of Medical Oncology, The Affiliated Tumour Hospital of Harbin Medical University, Harbin, Peopleâs Republic of China; 7Department of Breast Oncology, Guangzhou First People Hospital, Guangzhou, Peopleâs Republic of China; 8Department of Integrated Therapy in Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Peopleâs Republic of China; 9Department of Breast Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Peopleâs Re
- Published
- 2024